2024
Role of Vena Cava Filter in the Prophylaxis and Treatment of Venous Thromboembolism in Injured Adult Patients: A Systematic Review, Meta-Analysis, and Practice Management Guideline from the Eastern Association for the Surgery of Trauma [RETRACTED].
Bhattacharya B, Kodadek L, Nichiporenko I, Morrissey S, Kirsch J, Choi J, Ladhani H, Kasotakis G, Mukherjee K, Narsule C, Sharma R, Ruangvoravat L, Grushka J, Rattan R, Bugaev N. Role of Vena Cava Filter in the Prophylaxis and Treatment of Venous Thromboembolism in Injured Adult Patients: A Systematic Review, Meta-Analysis, and Practice Management Guideline from the Eastern Association for the Surgery of Trauma [RETRACTED]. Journal Of Trauma And Acute Care Surgery 2024 PMID: 38454308, DOI: 10.1097/ta.0000000000004289.Peer-Reviewed Original ResearchInferior vena cava filterInferior vena cavaQuality of evidenceDeep vein thrombosisInjured adult patientsRandomized controlled trialsVenous thromboembolismInjured patientsIVC filtersPulmonary embolismAdult patientsInferior vena cava filter useMeta-analysisEastern Association for the Surgery of TraumaTreatment of venous thromboembolismEvidence-based guidelinesPlacement of IVC filtersSystematic review/meta-analysisAcute venous thromboembolismVena cava filterPrevent venous thromboembolismPractice management guidelinesSurgery of TraumaLength of stayRecommendations AssessmentDevelopmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani C, Rashedi S, Lookstein R, Lansky A, Vedantham S, Sobieszczyk P, Mena-Hurtado C, Aghayev A, Henke P, Mehdipoor G, Tufano A, Chatterjee S, Middeldorp S, Wasan S, Bashir R, Lang I, Shishehbor M, Gerhard-Herman M, Giri J, Menard M, Parikh S, Mazzolai L, Moores L, Monreal M, Jimenez D, Goldhaber S, Krumholz H, Piazza G. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review. Seminars In Thrombosis And Hemostasis 2024, 50: 851-865. PMID: 38176425, DOI: 10.1055/s-0043-1777991.Peer-Reviewed Original ResearchVena cava interruptionDeep vein thrombosisInferior vena cavaVena cava filtersVenous thromboembolismPulmonary embolismVena cavaCava filtersProcedural interruptionsRisk of DVTBilateral deep vein thrombosisInfrarenal inferior vena cavaAcute venous thromboembolismLong-term complicationsSystemic adverse effectsSystemic venous circulationHigh-quality evidenceSuperior vena cavaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsIVC agenesisVein thrombosisYounger patientsThrombotic eventsRight atrium
2022
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.Peer-Reviewed Original ResearchPrevention of venous thromboembolismVenous thromboembolismOral anticoagulantsPediatric hematologistsClinically relevant nonmajor bleeding eventsTreatment of acute venous thromboembolismSecondary prevention of venous thromboembolismUS Food and Drug Administration approvalFood and Drug Administration approvalRecurrent thrombosis rateDirect oral anticoagulantsAcute venous thromboembolismNonmajor bleeding eventsPediatric venous thromboembolismDrug Administration approvalFemales aged >Prescribed DOACsDOAC useBleeding complicationsBleeding eventsMenstrual bleedingAnticoagulation regimenDOACsAdministration approvalOff-label
2013
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal Of Medicine 2013, 369: 799-808. PMID: 23808982, DOI: 10.1056/nejmoa1302507.Peer-Reviewed Original ResearchConceptsAcute venous thromboembolismConventional therapy groupPrimary efficacy outcomeVenous thromboembolismMajor bleedingConventional therapyApixaban groupRelevant nonmajorEfficacy outcomesRecurrent symptomatic venous thromboembolismOral factor Xa inhibitorsFixed-dose regimenPrincipal safety outcomeSymptomatic venous thromboembolismDouble-blind studyFactor Xa inhibitorsOral apixabanAdverse eventsComposite outcomeRelative riskThromboembolismXa inhibitorsApixabanSafety outcomesBleeding
2004
Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer
Tonnessen B, Money S. Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer. Perspectives In Vascular Surgery And Endovascular Therapy 2004, 16: 144-146. DOI: 10.1177/153100350401600217.Peer-Reviewed Original ResearchWeight heparin groupRecurrent venous thromboembolismRecurrent thromboembolismVenous thromboembolismWeight heparinAnticoagulation groupHeparin groupOpen-label clinical trialLowmolecular-weight heparinAcute venous thromboembolismOral anticoagulant therapyDeep vein thrombosisGroup of patientsMolecular weight heparinLower mortality rateOral anticoagulantsAnticoagulant therapyPulmonary embolismVein thrombosisCancer patientsClinical trialsEffective therapyThromboembolismMortality ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply